Vol. 4 No. 6 (2024)
Reimbursement Reviews

Ravulizumab (Ultomiris)

Published June 13, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ravulizumab (Ultomiris), 10 mg/mL and 100 mg/mL, concentrate for solution, IV infusion
  • Indication: For the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).